Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.352 5-Year IF: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i1-2.40
pages 29-35

p53-Based Immunotherapy of Cancer

Albert B. DeLeo
University of Pittsburgh Cancer Institute and Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213


Immunotherapy targeting p53 missense mutations, which occur in nearly half of all human tumors, is limited by several factors, including the constraints of antigen processing and presentation. Due to the accumulation of mutated p53 molecules in tumors expressing p53 mutations, an alternative approach would be to target wild-type sequence, CTL-defined p53 epitopes. Obviously, the possibility of an autoimmune response is a major potential drawback to this therapy. Immunization of BALB/c mice with bone marrow-derived dendritic cells (DC) generated in the presence of GM-CSF/IL-4 and prepulsed with the H-2Kd-binding wild-type p53232-240 peptide has been shown to induce anti-peptide CTL. These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53232-240 epitope, but not within it. Mitogen-activated splenocytes, which express elevated levels of p53, were not sensitive to these CTL. The p53 peptide-pulsed DC-based vaccine was shown to be effective in inducing tumor rejection in immunization and therapy models in the absence of any observable deleterious effect on naive mice. The murine model has now been extended to include the use of genetically modified DC-based vaccines as well.

Articles with similar content:

Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Flavio Arienti, Alessandro Borsatti, Paola Squarcina, Chiara Castelli, Filiberto Belli, Ettore Appella, Francesca Rini, Douglas J. Loftus, Francesco M. Marincola, Giorgio Parmiani, Licia Rivoltini, Carsten Geisler
Biological and Clinical Significance of Human NKRP1A/LLT1 Receptor/Ligand Interactions
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Jacek Malejczyk, Agata Bialoszewska
Parathyroid Hormone-Related Protein in Prostate Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 1
Subhash Kukreja, Farrokh Asadi
Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other"
Critical Reviews™ in Immunology, Vol.20, 2000, issue 6
Nicholas P. Restifo, Willem W. Overwijk
Targeting the Antigen-Binding Site of HLA-Restricting Alleles in Treatment of Autoimmune Disease
Critical Reviews™ in Immunology, Vol.27, 2007, issue 3
Philip Deitiker, M. Zouhair Atassi, Minako Oshima